Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as a formulation for intravenous use. It is employed to treat adult patients with certain solid tumours, primarily non‑small cell lung cancer and breast cancer, by interfering with microtubule assembly during cell division.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres and pharmacies worldwide in accordance with EU regulatory standards.

Vinorelbine is indicated for the treatment of solid tumours that are responsive to antimitotic chemotherapy.

- Non‑small cell lung cancer: improves disease control and prolongs survival in adult patients. - Breast cancer: used in combination regimens for advanced or metastatic disease.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea: sensation of queasiness often requiring anti‑emetic support. - Vomiting: forceful expulsion of stomach contents. - Constipation: decreased bowel movements. - Alopecia: hair thinning or loss. - Fatigue: persistent tiredness not relieved by rest.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Pulmonary toxicity: inflammation or fibrosis of lung tissue. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Peripheral neuropathy: tingling or numbness in extremities. - Cardiac arrhythmia: irregular heart rhythm that may need monitoring.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

- Blood count monitoring: perform regular CBC to detect neutropenia and anemia. - Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically. - Cardiac evaluation: obtain baseline ECG in patients with known heart disease. - Infection vigilance: postpone treatment in the presence of active severe infection. - Elderly caution: adjust monitoring frequency for patients over 65 years. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Warfarin: monitor INR as vinorelbine can affect coagulation. - Live vaccines: avoid during treatment due to immunosuppression.